ArticleProstate cancer and prostatic diseases2025
Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022.
Article in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Triple Clinical Filter Model for Selective Omission of Systematic Cores in Transperineal Cognitive Prostate Biopsy: A Retrospective Observational Study.The Prostate · 2026Observational
- Reference values for PSA, PSA density, and MRI prostate volume in healthy German men.European radiology · 2026Article
- Accelerating prostate MRI: a practical review of modern acquisition strategies.Abdominal radiology (New York) · 2026Review
- Integrating MRI-based tumour staging within the TNM classification system in modern prostate cancer management.Insights into imaging · 2026Review
- Active Surveillance Outcomes After Template-Guided Mapping Biopsy Among Patients With Prostate Cancer.JAMA network open · 2026Article
- AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study.European radiology · 2026Article
- Article
- Software mpMR/US fusion, cognitive, and in-bore biopsy: a comparative analysis of prostate cancer detection.International urology and nephrology · 2026Article
- Prostate MRI in the United Kingdom: a survey of current practice by the British Society of Urogenital Radiology.The British journal of radiology · 2026Article
- PROSTest, a Multigene Liquid Biopsy Signature, Effectively Stratifies Patients With High PSA for Prostate Biopsy.The Prostate · 2026Article
- Trends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021.Current urology · 2025Article
- Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study.The Journal of urology · 2025Article
- ProCUSNet: Prostate Cancer Detection on B-mode Transrectal Ultrasound Using Artificial Intelligence for Targeting During Prostate Biopsies.European urology oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundClinical guidelines favor MRI before prostate biopsy due to proven benefits. However, adoption patterns across the US are unclear.
methodsThis study used the Merative™ Marketscan® Commercial & Medicare Databases to analyze 872,829 prostate biopsies in 726,663 men from 2007-2022. Pre-biopsy pelvic MRI within 90 days was the primary outcome. Descriptive statistics and generalized estimating equations assessed changes over time, urban-rural differences, and state-level variation.
resultsPre-biopsy MRI utilization increased significantly from 0.5% in 2007 to 35.5% in 2022, with faster adoption in urban areas (36.1% in 2022) versus rural areas (28.3% in 2022). Geographic disparities were notable, with higher utilization in California, New York, and Minnesota, and lower rates in the Southeast and Mountain West.
conclusionsThe study reveals a paradigm shift in prostate cancer diagnostics towards MRI-guided approaches, influenced by evolving guidelines and clinical evidence. Disparities in access, particularly in rural areas and specific regions, highlight the need for targeted interventions to ensure equitable access to advanced diagnostic techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.